Aprea Therapeutics regains Nasdaq minimum bid price compliance

Aprea Therapeutics, Inc.

Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.
Regained compliance on March 1, 2023 after 10 consecutive trading days above $1.00 (Feb 14-28).
CEO Oren Gilad cited recent financing and progress on clinical asset ATRN-119 and pre-clinical ATRN-W1051.

item 8.01 item 9.01

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-027442

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.